Literature DB >> 15647454

Functional and molecular characterization of tachykinins and tachykinin receptors in the mouse uterus.

Eva Patak1, Francisco M Pinto, Margot E Story, C Oscar Pintado, Anna Fleming, Nigel M Page, Jocelyn N Pennefather, M Luz Candenas.   

Abstract

The aim of this study was to analyze the function and expression of tachykinins, tachykinin receptors, and neprilysin (NEP) in the mouse uterus. A previous study showed that the uterotonic effects of substance P (SP), neurokinin A (NKA), and neurokinin B (NKB) in estrogen-treated mice were mainly mediated by the tachykinin NK1 receptor. In the present work, further contractility studies were undertaken to determine the nature of the receptors mediating responses to tachykinins in uteri of late pregnant mice. Endpoint and real-time quantitative RT-PCR were used to analyze the expression of the genes that encode the tachykinins SP/NKA, NKB, and hemokinin-1 (HK-1) (Tac1, Tac2, and Tac4); and the genes that encode tachykinin NK1 (Tacr1), NK2 (Tacr2), and NK3 (Tacr3) receptors in uteri from pregnant and nonpregnant mice. The data show that the mRNAs of tachykinins (particularly NKB and HK-1), tachykinin receptors, and NEP are locally expressed in the mouse uterus, and their expression changes during the estrous cycle and during pregnancy. The tachykinin NK1 receptor is the predominant tachykinin receptor in the nonpregnant and early pregnant mouse and may mediate tachykinin-induced uterine contractions in the nonpregnant mouse. The tachykinin NK2 receptor is predominant in the late pregnant mouse and is the main receptor mediating uterotonic responses to tachykinins at late pregnancy. The tachykinin NK3 receptor is expressed in considerable amounts only in uteri from nonpregnant diestrous animals, and its physiological significance remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647454     DOI: 10.1095/biolreprod.104.036814

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  8 in total

Review 1.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

2.  Role of neurokinin-1 receptor in the initiation and maintenance of skin chronic inflammatory diseases.

Authors:  Sherrie J Divito; Adrian E Morelli; Adriana T Larregina
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

3.  Classical and membrane-initiated estrogen signaling in an in vitro model of anterior hypothalamic kisspeptin neurons.

Authors:  Melinda A Mittelman-Smith; Angela M Wong; Anupama S Q Kathiresan; Paul E Micevych
Journal:  Endocrinology       Date:  2015-03-02       Impact factor: 4.736

4.  Uncovering novel reproductive defects in neurokinin B receptor null mice: closing the gap between mice and men.

Authors:  Jasmine J Yang; Claudia S Caligioni; Yee-Ming Chan; Stephanie B Seminara
Journal:  Endocrinology       Date:  2012-01-17       Impact factor: 4.736

5.  Identification of Differentially Expressed Genes in Pelvic Organ Prolapse by RNA-Seq.

Authors:  Ruoyun Xie; Ying Xu; Shuixiu Fan; Yanfeng Song
Journal:  Med Sci Monit       Date:  2016-11-07

6.  Neuropeptides Substance P and Calcitonin Gene Related Peptide Accelerate the Development and Fibrogenesis of Endometriosis.

Authors:  Dingmin Yan; Xishi Liu; Sun-Wei Guo
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

7.  Ovarian steroids regulate tachykinin and tachykinin receptor gene expression in the mouse uterus.

Authors:  Francisco M Pinto; C Oscar Pintado; Jocelyn N Pennefather; Eva Patak; Luz Candenas
Journal:  Reprod Biol Endocrinol       Date:  2009-07-23       Impact factor: 5.211

8.  Analysis of the methylation of CpG islands in the CDO1, TAC1 and CHFR genes in pancreatic ductal cancer.

Authors:  Hiroshi Maekawa; Tomoaki Ito; Hajime Orita; Tomoyuki Kushida; Mutsumi Sakurada; Koichi Sato; Alicia Hulbert; Malcolm V Brock
Journal:  Oncol Lett       Date:  2020-01-23       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.